A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

Cantos [NCT01327846]

Description: The purpose of this trial is to test the hypothesis that canakinumab treatment of patients with MI at least one month prior to study entry and elevated hsCRP will prevent recurrent cardiovascular events.

Drug: Canakinumab 150 mg SQ; Drug: Canakinumab 50 mg SQ; Drug: Placebo

Primary Investigator: Kereiakes

Drug/Device Information
Prevention of recurrent cardiovascular events in stable post MI patients with high CRP at 1st study visit
Canakinumab - Human monoclonal antibody
Randomized to 150mgSQ /50mgSQ /placebo